Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gergely Solecki is active.

Publication


Featured researches published by Gergely Solecki.


Nature | 2015

Brain tumour cells interconnect to a functional and resistant network

Matthias Osswald; Erik Jung; Felix Sahm; Gergely Solecki; Varun Venkataramani; Jonas Blaes; Sophie Weil; Heinz Horstmann; Benedikt Wiestler; Mustafa Syed; Lulu Huang; Miriam Ratliff; Kianush Karimian Jazi; Felix T. Kurz; Torsten Schmenger; Dieter Lemke; Miriam Gömmel; Martin Pauli; Yunxiang Liao; Peter Häring; Stefan Pusch; Verena Herl; Christian Steinhäuser; Damir Krunic; Mostafa Jarahian; Hrvoje Miletic; Anna Sophie Berghoff; Oliver Griesbeck; Georgios Kalamakis; Olga Garaschuk

Astrocytic brain tumours, including glioblastomas, are incurable neoplasms characterized by diffusely infiltrative growth. Here we show that many tumour cells in astrocytomas extend ultra-long membrane protrusions, and use these distinct tumour microtubes as routes for brain invasion, proliferation, and to interconnect over long distances. The resulting network allows multicellular communication through microtube-associated gap junctions. When damage to the network occurred, tumour microtubes were used for repair. Moreover, the microtube-connected astrocytoma cells, but not those remaining unconnected throughout tumour progression, were protected from cell death inflicted by radiotherapy. The neuronal growth-associated protein 43 was important for microtube formation and function, and drove microtube-dependent tumour cell invasion, proliferation, interconnection, and radioresistance. Oligodendroglial brain tumours were deficient in this mechanism. In summary, astrocytomas can develop functional multicellular network structures. Disconnection of astrocytoma cells by targeting their tumour microtubes emerges as a new principle to reduce the treatment resistance of this disease.


Proceedings of the National Academy of Sciences of the United States of America | 2014

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy

Markus Weiler; Jonas Blaes; Stefan Pusch; Felix Sahm; Marcus Czabanka; Sebastian Luger; Lukas Bunse; Gergely Solecki; Viktoria Eichwald; Manfred Jugold; Sibylle Hodecker; Matthias Osswald; Christoph Meisner; Thomas Hielscher; Petra Rübmann; Philipp Niklas Pfenning; Michael W. Ronellenfitsch; Tore Kempf; Martina Schnölzer; Amir Abdollahi; Florian Lang; Martin Bendszus; Andreas von Deimling; Frank Winkler; Michael Weller; Peter Vajkoczy; Michael Platten; Wolfgang Wick

Significance N-myc downstream regulated gene 1 (NDRG1) is a central and druggable molecular hub integrating diverse therapy-induced microenvironmental factors to promote resistance toward alkylating chemotherapy. We suggest that NDRG1-mediated chemoprotection is achieved via binding and stabilizing methyltransferases, such as O6-methylguanine-DNA methyltransferase. A hypoxic microenvironment induces resistance to alkylating agents by activating targets in the mammalian target of rapamycin (mTOR) pathway. The molecular mechanisms involved in this mTOR-mediated hypoxia-induced chemoresistance, however, are unclear. Here we identify the mTOR target N-myc downstream regulated gene 1 (NDRG1) as a key determinant of resistance toward alkylating chemotherapy, driven by hypoxia but also by therapeutic measures such as irradiation, corticosteroids, and chronic exposure to alkylating agents via distinct molecular routes involving hypoxia-inducible factor (HIF)-1alpha, p53, and the mTOR complex 2 (mTORC2)/serum glucocorticoid-induced protein kinase 1 (SGK1) pathway. Resistance toward alkylating chemotherapy but not radiotherapy was dependent on NDRG1 expression and activity. In posttreatment tumor tissue of patients with malignant gliomas, NDRG1 was induced and predictive of poor response to alkylating chemotherapy. On a molecular level, NDRG1 bound and stabilized methyltransferases, chiefly O6-methylguanine-DNA methyltransferase (MGMT), a key enzyme for resistance to alkylating agents in glioblastoma patients. In patients with glioblastoma, MGMT promoter methylation in tumor tissue was not more predictive for response to alkylating chemotherapy in patients who received concomitant corticosteroids.


Journal of Cell Science | 2016

Fast and precise targeting of single tumor cells in vivo by multimodal correlative microscopy

Matthia A. Karreman; Luc Mercier; Nicole L. Schieber; Gergely Solecki; Guillaume Allio; Frank Winkler; Bernhard Ruthensteiner; Jacky G. Goetz; Yannick Schwab

ABSTRACT Intravital microscopy provides dynamic understanding of multiple cell biological processes, but its limited resolution has so far precluded structural analysis. Because it is difficult to capture rare and transient events, only a few attempts have been made to observe specific developmental and pathological processes in animal models using electron microscopy. The multimodal correlative approach that we propose here combines intravital microscopy, microscopic X-ray computed tomography and three-dimensional electron microscopy. It enables a rapid (c.a. 2 weeks) and accurate (<5 µm) correlation of functional imaging to ultrastructural analysis of single cells in a relevant context. We demonstrate the power of our approach by capturing single tumor cells in the vasculature of the cerebral cortex and in subcutaneous tumors, providing unique insights into metastatic events. Providing a significantly improved throughput, our workflow enables multiple sampling, a prerequisite for making correlative imaging a relevant tool to study cell biology in vivo. Owing to the versatility of this workflow, we envision broad applications in various fields of biological research, such as cancer or developmental biology. Highlighted Article: We provide here a novel correlative workflow combining intravital microscopy, microCT and 3D electron microscopy to reveal metastatic events in mouse brain and skin tissue at high resolution.


Clinical Cancer Research | 2016

Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.

Matthias Osswald; Jonas Blaes; Yunxiang Liao; Gergely Solecki; Miriam Gömmel; Anna-Sophie Berghoff; Laurent Salphati; Jeffrey Wallin; Heidi S. Phillips; Wolfgang Wick; Frank Winkler

Purpose: The role of blood–brain barrier (BBB) integrity for brain tumor biology and therapy is a matter of debate. Experimental Design: We developed a new experimental approach using in vivo two-photon imaging of mouse brain metastases originating from a melanoma cell line to investigate the growth kinetics of individual tumor cells in response to systemic delivery of two PI3K/mTOR inhibitors over time, and to study the impact of microregional vascular permeability. The two drugs are closely related but differ regarding a minor chemical modification that greatly increases brain penetration of one drug. Results: Both inhibitors demonstrated a comparable inhibition of downstream targets and melanoma growth in vitro. In vivo, increased BBB permeability to sodium fluorescein was associated with accelerated growth of individual brain metastases. Melanoma metastases with permeable microvessels responded similarly to equivalent doses of both inhibitors. In contrast, metastases with an intact BBB showed an exclusive response to the brain-penetrating inhibitor. The latter was true for macro- and micrometastases, and even single dormant melanoma cells. Nuclear morphology changes and single-cell regression patterns implied that both inhibitors, if extravasated, target not only perivascular melanoma cells but also those distant to blood vessels. Conclusions: Our study provides the first direct evidence that nonpermeable brain micro- and macrometastases can effectively be targeted by a drug designed to cross the BBB. Small-molecule inhibitors with these optimized properties are promising agents in preventing or treating brain metastases in patients. Clin Cancer Res; 22(24); 6078–87. ©2016 AACR. See related commentary by Steeg et al., p. 5953


Journal of Clinical Investigation | 2015

Proximity ligation assay evaluates IDH1R132H presentation in gliomas

Lukas Bunse; Theresa Schumacher; Felix Sahm; Stefan Pusch; Iris Oezen; Katharina J. Rauschenbach; Marina Gonzalez; Gergely Solecki; Matthias Osswald; David Capper; Benedikt Wiestler; Frank Winkler; Christel Herold-Mende; Andreas von Deimling; Wolfgang Wick; Michael Platten

For a targeted cancer vaccine to be effective, the antigen of interest needs to be naturally processed and presented on MHC by the target cell or an antigen-presenting cell (APC) in the tumor stroma. The presence of these characteristics is often assumed based on animal models, evaluation of antigen-overexpressing APCs in vitro, or assays of material-consuming immune precipitation from fresh solid tissue. Here, we evaluated the use of an alternative approach that uses the proximity ligation assay (PLA) to identify the presentation of an MHC class II-restricted antigen in paraffin-embedded tissue sections from patients with brain tumors. This approach required a specific antibody directed against the epitope that was presented. We used an antibody that specifically binds an epitope of mutated isocitrate dehydrogenase type 1 (IDH1R132H), which is frequently expressed in gliomas and other types of tumors. In situ PLA showed that the IDH1R132H epitope colocalizes with MHC class II in IDH1R132H-mutated glioma tissue. Moreover, PLA demonstrated colocalization between the class II epitope-containing melanoma antigen New York esophageal 1 and MHC class II. Collectively, our data suggest that PLA may be a useful tool to acquire information on whether an antigen is presented in situ, and this technique has potential to guide clinical studies that use antigen-specific cancer immunotherapy.


The Journal of Neuroscience | 2017

Tweety-homolog 1 drives brain colonization of gliomas

Erik Jung; Matthias Osswald; Jonas Blaes; Benedikt Wiestler; Felix Sahm; Torsten Schmenger; Gergely Solecki; Katrin Deumelandt; Felix T. Kurz; Ruifan Xie; Sophie Weil; Oliver Heil; Carina Thomé; Miriam Gömmel; Mustafa Syed; Peter Häring; Peter E. Huber; Sabine Heiland; Michael Platten; Andreas von Deimling; Wolfgang Wick; Frank Winkler

Early and progressive colonization of the healthy brain is one hallmark of diffuse gliomas, including glioblastomas. We recently discovered ultralong (>10 to hundreds of microns) membrane protrusions [tumor microtubes (TMs)] extended by glioma cells. TMs have been associated with the capacity of glioma cells to effectively invade the brain and proliferate. Moreover, TMs are also used by some tumor cells to interconnect to one large, resistant multicellular network. Here, we performed a correlative gene-expression microarray and in vivo imaging analysis, and identified novel molecular candidates for TM formation and function. Interestingly, these genes were previously linked to normal CNS development. One of the genes scoring highest in tests related to the outgrowth of TMs was tweety-homolog 1 (TTYH1), which was highly expressed in a fraction of TMs in mice and patients. Ttyh1 was confirmed to be a potent regulator of normal TM morphology and of TM-mediated tumor-cell invasion and proliferation. Glioma cells with one or two TMs were mainly responsible for effective brain colonization, and Ttyh1 downregulation particularly affected this cellular subtype, resulting in reduced tumor progression and prolonged survival of mice. The remaining Ttyh1-deficient tumor cells, however, had more interconnecting TMs, which were associated with increased radioresistance in those small tumors. These findings imply a cellular and molecular heterogeneity in gliomas regarding formation and function of distinct TM subtypes, with multiple parallels to neuronal development, and suggest that Ttyh1 might be a promising target to specifically reduce TM-associated brain colonization by glioma cells in patients. SIGNIFICANCE STATEMENT In this report, we identify tweety-homolog 1 (Ttyh1), a membrane protein linked to neuronal development, as a potent driver of tumor microtube (TM)-mediated brain colonization by glioma cells. Targeting of Ttyh1 effectively inhibited the formation of invasive TMs and glioma growth, but increased network formation by intercellular TMs, suggesting a functional and molecular heterogeneity of the recently discovered TMs with potential implications for future TM-targeting strategies.


Developmental Cell | 2017

YAP/TAZ Orchestrate VEGF Signaling during Developmental Angiogenesis

Xiaohong Wang; Aida Freire Valls; Géza Schermann; Ying Shen; Iván M. Moya; Laura Castro; Severino Urban; Gergely Solecki; Frank Winkler; Lars Riedemann; Rakesh K. Jain; Massimilano Mazzone; Thomas Schmidt; Tamás Fischer; Georg Halder; Carmen Ruiz de Almodovar

Vascular endothelial growth factor (VEGF) is a major driver of blood vessel formation. However, the signal transduction pathways culminating in the biological consequences of VEGF signaling are only partially understood. Here, we show that the Hippo pathway effectors YAP and TAZ work as crucial signal transducers to mediate VEGF-VEGFR2 signaling during angiogenesis. We demonstrate that YAP/TAZ are essential for vascular development as endothelium-specific deletion of YAP/TAZ leads to impaired vascularization and embryonic lethality. Mechanistically, we show that VEGF activates YAP/TAZ via its effects on actin cytoskeleton and that activated YAP/TAZ induce a transcriptional program to further control cytoskeleton dynamics and thus establish a feedforward loop that ensures a proper angiogenic response. Lack of YAP/TAZ also results in altered cellular distribution of VEGFR2 due to trafficking defects from the Golgi apparatus to the plasma membrane. Altogether, our study identifies YAP/TAZ as central mediators of VEGF signaling and therefore as important regulators of angiogenesis.


eLife | 2016

Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis

Michael O. Breckwoldt; Julia Bode; Felix T. Kurz; Angelika Hoffmann; Katharina Ochs; Martina Ott; Katrin Deumelandt; Thomas Krüwel; Daniel Schwarz; Xavier Helluy; David Milford; Klara Kirschbaum; Gergely Solecki; Sara Chiblak; Amir Abdollahi; Frank Winkler; Wolfgang Wick; Michael Platten; Sabine Heiland; Martin Bendszus; Björn Tews

Neoangiogenesis is a pivotal therapeutic target in glioblastoma. Tumor monitoring requires imaging methods to assess treatment effects and disease progression. Until now mapping of the tumor vasculature has been difficult. We have developed a combined magnetic resonance and optical toolkit to study neoangiogenesis in glioma models. We use in vivo magnetic resonance imaging (MRI) and correlative ultramicroscopy (UM) of ex vivo cleared whole brains to track neovascularization. T2* imaging allows the identification of single vessels in glioma development and the quantification of neovessels over time. Pharmacological VEGF inhibition leads to partial vascular normalization with decreased vessel caliber, density, and permeability. To further resolve the tumor microvasculature, we performed correlated UM of fluorescently labeled microvessels in cleared brains. UM resolved typical features of neoangiogenesis and tumor cell invasion with a spatial resolution of ~5 µm. MR-UM can be used as a platform for three-dimensional mapping and high-resolution quantification of tumor angiogenesis. DOI: http://dx.doi.org/10.7554/eLife.11712.001


Neuro-oncology | 2018

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma

Eskil Eskilsson; Gro Vatne Røsland; Gergely Solecki; Qianghu Wang; Patrick N. Harter; Grazia Graziani; Roel G.W. Verhaak; Frank Winkler; Rolf Bjerkvig; Hrvoje Miletic

Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need of effective treatment strategies. Recent advances in sequencing techniques unraveled the complete genomic landscape of GBMs and revealed profound heterogeneity of individual tumors even at the single cell level. Genomic profiling has detected epidermal growth factor receptor (EGFR) gene alterations in more than half of GBMs. Major genetic events include amplification and mutation of EGFR. Yet, treatment strategies targeting EGFR have thus far failed in clinical trials. In this review, we discuss the clonal and functional heterogeneity of EGFRs in GBM development and critically reassess the potential of EGFRs as therapeutic targets.


Magnetic Resonance Materials in Physics Biology and Medicine | 2018

Vessel radius mapping in an extended model of transverse relaxation

L.R. Buschle; Christian H. Ziener; Ke Zhang; V. Sturm; Thomas Kampf; Artur Hahn; Gergely Solecki; Frank Winkler; Martin Bendszus; Sabine Heiland; Heinz Peter Schlemmer; Felix T. Kurz

ObjectivesSpin dephasing of the local magnetization in blood vessel networks can be described in the static dephasing regime (where diffusion effects may be ignored) by the established model of Yablonskiy and Haacke. However, for small capillary radii, diffusion phenomena for spin-bearing particles are not negligible.Material and methodsIn this work, we include diffusion effects for a set of randomly distributed capillaries and provide analytical expressions for the transverse relaxation times T2* and T2 in the strong collision approximation and the Gaussian approximation that relate MR signal properties with microstructural parameters such as the mean local capillary radius.ResultsTheoretical results are numerically validated with random walk simulations and are used to calculate capillary radius distribution maps for glioblastoma mouse brains at 9.4 T. For representative tumor regions, the capillary maps reveal a relative increase of mean radius for tumor tissue towards healthy brain tissue of

Collaboration


Dive into the Gergely Solecki's collaboration.

Top Co-Authors

Avatar

Frank Winkler

German Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Wolfgang Wick

German Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Matthias Osswald

German Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Jonas Blaes

German Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Julia Grosch

German Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Matthia A. Karreman

European Bioinformatics Institute

View shared research outputs
Top Co-Authors

Avatar

Yannick Schwab

European Bioinformatics Institute

View shared research outputs
Top Co-Authors

Avatar

Luc Mercier

University of Strasbourg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martin Bendszus

University Hospital Heidelberg

View shared research outputs
Researchain Logo
Decentralizing Knowledge